# Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

> **NCT01363700** · PHASE3 · COMPLETED · sponsor: **Santen Pharmaceutical Co., Ltd.** · enrollment: 87 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** DE-114 ophthalmic solution
- **DRUG:** Placebo ophthalmic solution
- **DRUG:** Olopatadine Hydrochloride 0.1% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT01363700
- **Lead sponsor:** Santen Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** 2012-06
- **Final completion:** —
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2014-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01363700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01363700, "Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01363700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*